Exiqon A/S
Exiqon launches Next Generation Sequencing services

DGAP-News: Exiqon A/S /

21.01.2014 / 13:11

---------------------------------------------------------------------

Exiqon A/S (NASDAQ OMX: EXQ), a leading supplier of high-value gene expression
analysis products, today announced the launch of its new Next Generation
Sequencing services for microRNAs and other RNAs. 

Exiqon's Next Generation Sequencing services provide a complete
sample-to-answer solution including biological interpretation of customer's
results. Results are delivered within 4-6 weeks of sample submission. All
customers receive results and data analyses in the form of a highly advanced
interactive report. The interactive report summarizes results in simple tables
and diagrams and provides easy access to identify interesting microRNAs and
genes through use of Exiqon's proprietary miRSearch bioinformatics search tool
which saves time and effort compared to traditional literature and database
searches by rapidly presenting relevant information. 

'This product offering is based on years of collaboration with our customers
and numerous man-years of product development. Valuable customer input has
defined the importance of combining high quality, fast turnaround time and
thorough in depth reporting that can be readily understood by customers without
prior training in Next Generation Sequencing' said Senior Vice President Sales
& Marketing, Dr. Henrik M. Pfundheller. 

The new offer for Next Generation Sequencing services complements Exiqon's
existing portfolio of services for qPCR and microarray profiling and allows
Exiqon to leverage 9 years of experience in servicing customers with high
quality data through modern service laboratories. 

Exiqon's Next Generation Sequencing services integrate technical support in the
planning phase with advanced sample preparation, library preparation, sequence
generation based on state-of-the-art equipment and proprietary data analysis.
These services address the need in basic research to reveal known as well as
unknown microRNAs and other RNAs. Exiqon also offers a full range of
LNA(TM)-enhanced qPCR products for validation of targets identified by Next
Generation Sequencing and LNA(TM) products for any down-stream functional
analysis. 

Additional information is available at www.exiqon.com/NGS-services

A sample of the data report can be downloaded at
www.exiqon.com/ls/Documents/Scientific/NGS-Service-Flyer.pdf 

Additional information
Lars Kongsbak, Presidents and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, SVP Sales & Marketing, tel. +45 4565 0420 (cell: +45
4090 2106)
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

21.01.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English       
Company:     Exiqon A/S    
 
 
             Denmark       
ISIN:        DK0060077758  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
248897 21.01.2014